RemeGen Co., Ltd.

SEHK:9995 Stock Report

Market Cap: HK$60.6b

RemeGen Future Growth

Future criteria checks 2/6

RemeGen's earnings are forecast to decline at 2% per annum while its annual revenue is expected to grow at 11.6% per year. EPS is expected to decline by 3.9% per annum. Return on equity is forecast to be 22.8% in 3 years.

Key information

-2.0%

Earnings growth rate

-3.93%

EPS growth rate

Biotechs earnings growth30.6%
Revenue growth rate11.6%
Future return on equity22.76%
Analyst coverage

Good

Last updated22 Jun 2026

Recent future growth updates

Recent updates

Analysis Article • Jun 19

RemeGen (SEHK:9995) Stock Could Be 39% Below Fair Value After Telitacicept Approvals

RemeGen (SEHK:9995) is back in focus after China’s National Medical Products Administration approved new indications for its autoimmune drug Telitacicept in Sjögren’s disease and conditionally in IgA nephropathy, expanding its treated patient pools. See our latest analysis for RemeGen. At a latest share price of HK$68.5, RemeGen’s 1 day share price return of 1.63% follows a 30 day share price decline of 19.32%. Its 1 year total shareholder return of 37.27% and 3 year total shareholder return...
Analysis Article • Apr 03

RemeGen (HKG:9995) Is Posting Healthy Earnings, But It Is Not All Good News

After announcing healthy earnings, RemeGen Co., Ltd.'s ( HKG:9995 ) stock rose over the last week. Despite the strong...
Analysis Article • Jan 13

Subdued Growth No Barrier To RemeGen Co., Ltd. (HKG:9995) With Shares Advancing 27%

RemeGen Co., Ltd. ( HKG:9995 ) shares have had a really impressive month, gaining 27% after a shaky period beforehand...
Analysis Article • Jan 03

RemeGen Co., Ltd.'s (HKG:9995) Intrinsic Value Is Potentially 38% Above Its Share Price

Key Insights The projected fair value for RemeGen is HK$102 based on 2 Stage Free Cash Flow to Equity RemeGen is...
Analysis Article • Sep 18

What RemeGen Co., Ltd.'s (HKG:9995) 32% Share Price Gain Is Not Telling You

Despite an already strong run, RemeGen Co., Ltd. ( HKG:9995 ) shares have been powering on, with a gain of 32% in the...
Analysis Article • Aug 27

Need To Know: Analysts Are Much More Bullish On RemeGen Co., Ltd. (HKG:9995) Revenues

Celebrations may be in order for RemeGen Co., Ltd. ( HKG:9995 ) shareholders, with the analysts delivering a...
Analysis Article • Jul 29

RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 26% But Its Business Is Yet to Catch Up

Despite an already strong run, RemeGen Co., Ltd. ( HKG:9995 ) shares have been powering on, with a gain of 26% in the...

Earnings and Revenue Growth Forecasts

SEHK:9995 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20286,0421,5491,6511,68311
12/31/20274,7708531,5701,48514
12/31/20267,0253,5353,0563,50713
3/31/20263,3811,29243253N/A
12/31/20253,251710-14753N/A
9/30/20252,228-948-323-62N/A
6/30/20252,073-1,137-784-540N/A
3/31/20251,912-1,374-1,088-876N/A
12/31/20241,717-1,468-1,380-1,114N/A
9/30/20241,522-1,552-1,544-1,223N/A
6/30/20241,402-1,588-2,178-1,615N/A
3/31/20241,245-1,536-2,354-1,579N/A
12/31/20231,083-1,511-2,356-1,503N/A
9/30/2023972-1,341-2,150-1,295N/A
6/30/2023844-1,213-2,071-1,269N/A
3/31/2023790-1,036-2,007-1,260N/A
12/31/2022772-999-2,013-1,260N/A
9/30/20221,879276-894-97N/A
6/30/20221,745231-60990N/A
3/31/20221,570174-474185N/A
12/31/20211,424276-354264N/A
9/30/2021115-912-1,483-921N/A
6/30/202129-892-1,493-927N/A
3/31/20214-783-1,326-814N/A
12/31/2020N/A-698-1,141-660N/A
9/30/2020N/A-588-906-543N/A
6/30/2020N/A-478-671-427N/A
3/31/2020N/A-442-487-343N/A
12/31/2019N/A-430N/A-283N/A
12/31/201811-270N/A-128N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 9995's earnings are forecast to decline over the next 3 years (-2% per year).

Earnings vs Market: 9995's earnings are forecast to decline over the next 3 years (-2% per year).

High Growth Earnings: 9995's earnings are forecast to decline over the next 3 years.

Revenue vs Market: 9995's revenue (11.6% per year) is forecast to grow faster than the Hong Kong market (8.9% per year).

High Growth Revenue: 9995's revenue (11.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 9995's Return on Equity is forecast to be high in 3 years time (22.8%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/29 12:52
End of Day Share Price 2026/06/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

RemeGen Co., Ltd. is covered by 29 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhishun SiuCCB International Securities Limited
Shun Kei LawCCB International Securities Limited
Jin ZhangChina International Capital Corporation Limited